Conference Presentations
ESMO 2025
Phase II trial of neoadjuvant PD-1 vaccine PD1- Vaxx in operable MSI-high colorectal cancer
Cholangiocarcinoma Foundation Annual Conference (CFAC) 2025
Treatment of Cholangiocarcinoma with the Oncolytic Virus CF33-hNIS (Presented by Imugene’s Senior Director, Translational Research Grey Wilkinson)
Imugene Investor Presentation: NWR Communications Virtual Healthcare Conference (Presented by CEO & Managing Director Leslie Chong)
2025 ASTCT and CIBMTR Tandem Meetings
Administration of Low-Dose, Subcutaneous (SC) Interleukin-2 (IL-2) Markedly Enhances the Pharmacokinetic (PK) Profile of Azercabtagene Zapreleucel (azer-cel), an Allogeneic Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, without Compromising Safety and Early Evidence of Clinical Activity in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Have Relapsed after Prior CD19-Directed CAR T-Cell Products Presenting author: Dr. Paul Woodard M.D. Imugene Chief Medical Officer.
ESMO 2024
Final results of the Phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy, in patients with HER2-overexpressing advanced gastric cancer – (HERIZON) (Presented by Joshua Tobias Ph.D)
San Antonio Breast Cancer Symposium (SABC)
Tumor size reduction and overall survival improvement in HER2-overexpressing gastric cancer (presented by Joshua Tobias Ph.D)
2024 American Society of Clinical Oncology (ASCO) Presentation
Combination Therapy with the Oncolytic Virus CF33-CD19 and Blinatumomab for the Treatment of Advanced Solid Tumors (presented by Dr Paul Woodward)
2024 Cholangiocarcinoma Annual Conference Poster Presentation
CF33-hNIS, a novel oncolytic virus for the treatment of cholangiocarcinoma and biliary tract malignancies (presented by Dr Paul Woodward)
2024 American Association for Cancer Research (AACR) Poster Presentation
Oncolytic virus CF33-hNIS for the treatment of advanced cancer (presented by Dr. Daneng Li)
2024 American Association for Cancer Research (AACR) Poster Presentation
Frontline vaccination with the B-cell peptide compound HER-Vaxx (IMU-131), combined with standard-of-care chemotherapy induces high levels of HER2-specific antibodies mediating ADCC and intracellular phosphorylation inhibition resulting in overall survival benefit in patients with HER2+ metastatic or advanced gastric/GEJ adenocarcinoma – Final results from Phase II/HERIZON study (presented by Joshua Tobias Ph.D)
ASX Small and Mid-Cap Conference 2024
Developing Cancer Immunotherapies (presented by Dr Nick Ede)
2024 ASCO Gastrointestinal Cancers Symposium